For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Aneurysmal Subarachnoid Hemorrhage Treatment Study
The purpose of this study is to investigate the safety and clinical effect of a continuous low-dose intravenous heparin treatment in patients who have an aneurysmal subarachnoid hemorrhage. Nationwide, 88 patients will be recruited for this study. At Rush University, we expect to recruit 8 patients. Treatment will be assigned randomly between low-dose intravenous heparin and prophylactic subcutaneous heparin (standard of care).
In order to participate you must meet the following criteria:
- Are between the ages of 18 and 70 years old.
- Have a ruptured saccular aneurysm confirmed by angiography and repaired by coiling.
- Have GCS 13-15 without focal deficit after repair.
- Have odified Fisher 3 only (minimal IVH allowed).
You will be excluded from the study if any of the following criteria apply to you:
- Have clipping or intracranial stent placement.
- Have anti-platelet or oral anticoagulation prior or during coil (single dose 325mg ASA is OK).
- Have a body weight < 50 or > 150kg.
- Have historical mRS ≥ 2.
This is a partial list of inclusion and exclusion criteria.